These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Research collaboration covers multiple antibody research programs
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
With this commissioning, Shilpa Medicare joins a very small group of Indian companies capable of offering end-to-end ADC Drug Substance development and manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
